

# Integrin Beta 7 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/I84EE4EBE356EN.html>

Date: June 2020

Pages: 64

Price: US\$ 3,500.00 (Single User License)

ID: I84EE4EBE356EN

## Abstracts

Integrin Beta 7 - Pipeline Review, H1 2020

### SUMMARY

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease).

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 9 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 1, 4 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Immunology and Infectious Disease which include indications Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS) and Inflammation.

The latest report Integrin Beta 7 – Pipeline Review, H1 2020, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in  
Therapeutics Development

Aviara Pharmaceuticals Inc

C4X Discovery Holdings Plc

Genentech Inc

Gilead Sciences Inc

Morphic Holding Inc

Polpharma Biologics

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Zealand Pharma AS

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles

etrolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-1427 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development

Milestones  
Featured News & Press Releases  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indication, H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by Avira Pharmaceuticals Inc, H1 2020  
Pipeline by C4X Discovery Holdings Plc, H1 2020  
Pipeline by Genentech Inc, H1 2020  
Pipeline by Gilead Sciences Inc, H1 2020  
Pipeline by Morphic Holding Inc, H1 2020  
Pipeline by Polpharma Biologics, H1 2020  
Pipeline by Protagonist Therapeutics Inc, H1 2020  
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020  
Pipeline by Zealand Pharma AS, H1 2020  
Dormant Projects, H1 2020  
Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Aviara Pharmaceuticals Inc

C4X Discovery Holdings Plc

Genentech Inc

Gilead Sciences Inc

Morphic Holding Inc

Polpharma Biologics

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Zealand Pharma AS

## I would like to order

Product name: Integrin Beta 7 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/l84EE4EBE356EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l84EE4EBE356EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970